MedinCell S.A. (EPA: MEDCL)

Market Cap	474.10M
Revenue (ttm)	13.20M
Net Income (ttm)	-31.45M
Shares Out	29.23M
EPS (ttm)	-1.08
PE Ratio	n/a
Forward PE	60.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,244
Average Volume	54,831
Open	16.34
Previous Close	16.30
Day's Range	16.18 - 16.40
52-Week Range	8.06 - 19.00
Beta	1.22
RSI	43.84
Earnings Date	Jun 17, 2025

About MedinCell

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 134
• Stock Exchange: Euronext Paris
• Ticker Symbol: MEDCL

Financial Performance

In 2023, MedinCell's revenue was 11.95 million, a decrease of -12.52% compared to the previous year's 13.66 million. Losses were -25.04 million, -21.78% less than in 2022.